Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Abstract Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS. However, tocilizumab and siltuximab are expensive and some pati...

Full description

Bibliographic Details
Main Authors: Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li, Lijuan Chen
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Experimental Hematology & Oncology
Subjects:
Tumor necrosis factor -α
Etanercept
Cytokine release syndrome
Chimeric antigen receptor T cell therapy
Multiple myeloma
Online Access:https://doi.org/10.1186/s40164-021-00209-2

Similar Items

Similar Items